<DOC>
	<DOC>NCT01111344</DOC>
	<brief_summary>The purpose of the study is to assess the efficacy of Glizigen and Viusid administration in the treatment of external anogenital warts in children and adolescents. The duration of this double-blind placebo controlled phase 3 clinical trial will be 12 weeks. The estimated number of persons to be recruited and randomized for the study is 76. Variables to be assessed will be: time to disappearance of lesions, reduction of the number of lesions and change in the aspect of lesions.</brief_summary>
	<brief_title>Glizigen-Viudid-External Anogenital Warts in Children and Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<criteria>No previous treatment for anogenital warts Negative serology for HB and HIV. Signed informed consent. Pregnancy Treatment with steroids, immunesuppressors, immunemodulators or local or systemic antiviral drugs. Hypersensitivity to Glizigen or Viusid:</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Dietary supplement</keyword>
	<keyword>Anogenital warts</keyword>
	<keyword>Viusid</keyword>
	<keyword>Glizigen</keyword>
</DOC>